Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 12 of 43

Clinical Questions Addressed by the Comparative Effectiveness Review (1 of 2)

The literature reviewed for the comparative effectiveness review was limited to studies performed in children, adolescents, and young adults from 1 to 24 years of age.

Key Questions addressed by the review included:

What is the comparative efficacy or effectiveness of first-generation (FGAs) and second-generation (SGAs) antipsychotics for treating disorder-specific and nonspecific symptoms?

Do FGAs and SGAs differ in short-term (within 6 months) and long-term (after 6 months) outcomes, including:

  • Response rate and relationship to dosage; speed of response; duration of response; remission; relapse; time to discontinuation; and adherence
  • Growth and maturation; cognitive and emotional development
  • Suicidal behaviors and ideation
  • Work-related functional capacity; school performance
  • Patient insight into illness
  • Medication adherence
  • Patient- or caregiver-reported outcomes
  • Health-related quality of life
  • Legal or justice system interactions
  • Health care system utilization